pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells

被引:0
|
作者
Kobayashi, K
Bouscarel, B
Matsuzaki, Y
Ceryak, S
Kudoh, S
Fromm, H
机构
[1] George Washington Univ, Med Ctr, Div Gastroenterol & Nutr, Washington, DC 20037 USA
[2] Nippon Med Sch, Dept Internal Med 4, Tokyo 113, Japan
[3] George Washington Univ, Dept Biochem & Mol Biol, Washington, DC USA
[4] Univ Tsukuba, Div Gastroenterol, Ibaraki, Osaka, Japan
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Irinotecan (CPT-11) and its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), are believed to be reabsorbed by intestinal cells and to enter the entero-hepatic circulation, but there is little information to date. Our objective was to investigate the intestinal transport of CPT-11 and SN-38 in correlation with their associated cytotoxicity. Using either isolated hamster intestinal epithelial cells or/and human colon carcinoma HT29 cells, the uptake rates of [C-14]CPT-11 and [C-14]SN-38, both as respective non-ionic lactone form at acidic pH and anionic carboxylate form at basic pH, were investigated by the rapid vacuum filtration technique. The effect of physiologic intestinal luminal pH (6.2-8.0) on the uptake rate and cytotoxicity of SN-38 were estimated by the above method and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay, respectively. The lactone forms of CPT-11 and SN-38 were transported passively, while the respective carboxylate form was absorbed actively. Uptake rates of both lactones were significantly higher than those of their carboxylates, Under physiologic pH, the respective uptake rates of CPT-11 and SN-38 were pH sensitive and decreased significantly by around 65%, at pH greater than 6.8. Furthermore, with decreasing pH, a higher uptake rate of SN-38 into HT29 cells correlates with a greater cytotoxic effect (r = 0.987). CPT-11 and SN-38 have absorption characteristics of weakly basic drugs such as short-chain fatty acids, suggesting that alkalization of the intestinal lumen may be critical to reduce their reabsorption and associated side effects. Int. J. Cancer 83:491-496, 1999. (C) 1999 Wiley-Liss, Inc.
引用
收藏
页码:491 / 496
页数:6
相关论文
共 50 条
  • [41] Role of Mrp3-mediated efflux in systemic exposure of SN-38, the active metabolite of irinotecan
    Kitamura, Yoshiaki
    Kusuhara, Hiroyuki
    Sugiyama, Yuichi
    DRUG METABOLISM REVIEWS, 2010, 42 : 288 - 288
  • [42] Effective irinotecan (CPT-11)-containing liposomes: Intraliposomal conversion to the active metabolite SN-38
    Sadzuka, Y
    Hirotsu, S
    Hirota, S
    JAPANESE JOURNAL OF CANCER RESEARCH, 1999, 90 (02): : 226 - 232
  • [43] Distribution and quantification of irinotecan and its active metabolite SN-38 in colon cancer murine model systems using MALDI MSI
    Buck, Achim
    Halbritter, Susanne
    Spaeth, Christoph
    Feuchtinger, Annette
    Aichler, Michaela
    Zitzelsberger, Horst
    Janssen, Klaus-Peter
    Walch, Axel
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2015, 407 (08) : 2107 - 2116
  • [44] Distribution and quantification of irinotecan and its active metabolite SN-38 in colon cancer murine model systems using MALDI MSI
    Achim Buck
    Susanne Halbritter
    Christoph Späth
    Annette Feuchtinger
    Michaela Aichler
    Horst Zitzelsberger
    Klaus-Peter Janssen
    Axel Walch
    Analytical and Bioanalytical Chemistry, 2015, 407 : 2107 - 2116
  • [45] Inhibition of SN-38 glucuronidation by gefitinib and its metabolite
    Wei Li
    Yafei Xing
    Yong Liu
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 1253 - 1260
  • [46] SN-38, an active metabolite of irinotecan-induced apoptosis in human hepatoma cells is involved by activation of p53
    Takeba, Yuko
    Kumai, Toshio
    Matsumoto, Naoki
    Kobayashi, Shinichi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2007, 103 : 158P - 158P
  • [47] Inhibition of SN-38 glucuronidation by gefitinib and its metabolite
    Li, Wei
    Xing, Yafei
    Liu, Yong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (06) : 1253 - 1260
  • [48] In Vitro Binding and Partitioning of Irinotecan (CPT-11) and its Metabolite, SN-38, in Human Blood
    Olivier Combes
    Jérôme Barré
    Jean-Claude Duché
    Laurent Vernillet
    Yves Archimbaud
    Michael P. Marietta
    Jean-Paul Tillement
    Saïk Urien
    Investigational New Drugs, 2000, 18 : 1 - 5
  • [49] In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood
    Combes, O
    Barré, J
    Duché, JC
    Vernillet, L
    Archimbaud, Y
    Marietta, MP
    Tillement, JP
    Urien, S
    INVESTIGATIONAL NEW DRUGS, 2000, 18 (01) : 1 - 5
  • [50] Liposomalization of SN-38 as active metabolite of CPT-11
    Sadzuka, Y
    Takabe, H
    Sonobe, T
    JOURNAL OF CONTROLLED RELEASE, 2005, 108 (2-3) : 453 - 459